MediciNova Announces That The National Institutes Of Health Neurological Disorders And Stroke Has Awarded $22M For An Intermediate Size Expanded Access Protocol To Evaluate The Efficacy Of MN-166 In Amyotrophic Lateral Sclerosis

BenzingaSep 30 09:05 ET

Express News | MediciNova Inc - Nih Awards $22 Million for Eap to Evaluate Mn-166 in ALS

ReutersSep 30 09:00 ET

Express News | Medicinova to Support Nih-Funded Expanded Access Clinical Trial to Evaluate Mn166 (Ibudilast) in Amyotrophic Lateral Sclerosis (ALS)

ReutersSep 30 09:00 ET

Medicinova and others continue to rank in, with clinical trials starting for ALS (amyotrophic lateral sclerosis) treatments.

Medicinova <4875> has ranked in (as of 10:32). It is significantly up. On the 23rd yesterday, it was announced that the company has received new Expand Access Program research grants from the National Institutes of Health (NIH) in the USA, and has initiated clinical trials targeting ALS patients with MN-166 (Ibudilast) being developed, being considered a buying catalyst. Details are being coordinated with relevant agencies.

Fisco JapanSep 23 21:36 ET

Volume change rate ranking (9:00) - Rain, Wind, Sun, Ange's, etc. are ranked.

* In the volume change rate ranking, you can understand the interest of market participants, such as the trend of trading, by comparing the average volume of the recent 5 days with the volume on the delivery day. * Top Volume Change Rate [As of September 20th, 9:32] (Comparison of average volume of the recent 5 days) Stock code Stock name Volume 5-day average volume Volume change rate Stock price change rate <9058> Tracom 542,400 107,185.08 248.86% 0.007

Fisco JapanSep 19 20:57 ET

MediciNova: Confirmatory letter.

EDINETSep 10 22:32 ET · Announcements